Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYCCP SEC filings page on Stock Titan aggregates regulatory documents for Cyclacel Pharmaceuticals, Inc., the issuer of the 6% Convertible Exchangeable Preferred Stock trading under symbol CYCCP on The Nasdaq Capital Market. These filings provide detailed information on the company’s oncology development activities, capital structure and corporate changes, and are a primary source for understanding the rights and risks associated with the preferred stock.
Investors can review Form 8-K current reports that describe material events such as private placements of Series F Convertible Preferred Stock and related series A, B and C common stock purchase warrants, warrant exchange agreements, amendments to preferred stock terms, and reverse stock splits of the common stock. Certain 8-K filings also discuss changes in the company’s independent registered public accounting firm and include the prior auditor’s statement that limited cash resources raised substantial doubt about the company’s ability to continue as a going concern.
Filings linked to CYCCP also cover shareholder approvals and strategic transactions. For example, an 8-K details the results of a special meeting where shareholders approved the issuance of Cyclacel common stock to FITTERS Diversified Berhad in connection with the acquisition of Fitters Sdn. Bhd., the potential issuance of more than 20% of the outstanding common stock under Nasdaq rules, and an amendment to change the corporate name to Bio Green Med Solution, Inc. Additional 8-K and 8-K/A filings note the adoption of an updated logo and reference the company’s new name and ticker symbol for its securities.
Registration statements such as the Form S-1 provide further context by registering shares of common stock underlying the Series F Preferred Stock and warrants, and by including business descriptions that characterize Cyclacel as a clinical-stage biopharmaceutical company focused on cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology. These documents often incorporate audited or reviewed financial statements and risk factor discussions.
On Stock Titan, AI-powered tools summarize key points from lengthy filings, highlight items relevant to CYCCP holders—such as dividend rights, conversion features, ownership limitations and subsequent amendments—and surface disclosures on liquidity, going concern language and major transactions. Real-time updates from EDGAR mean new 8-K, 10-Q, 10-K, S-1 and related filings appear promptly, enabling users to quickly see how Cyclacel’s preferred stock, common equity and corporate profile are described in its official SEC submissions.
Bio Green Med Solution, Inc. completed a major strategic pivot in 2025, exiting most drug development and becoming a Malaysia-focused supplier and trader of fire safety equipment through the acquisition of Fitters Sdn. Bhd. for 699,158 new common shares, equal to 19.99% of its stock.
The company deconsolidated its former R&D subsidiary Cyclacel Limited after a creditors’ voluntary liquidation, increasing stockholders’ equity by about $4.9 million, then repurchased and later sold its Plogosertib assets for up to $470,000. It raised $3.1 million via Series C and D preferred stock and later concentrated ownership in a new investor.
BGMS now distributes certified fire extinguishers, foam systems, PYRODOR fire doors, PPE and safety apparel into Malaysian commercial, industrial and government markets, but highlights substantial doubt about its ability to continue as a going concern, high customer concentration, intense competition, regulatory dependence and the need for additional capital.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. amendment to a Schedule 13G/A reports that Ong Yee Lung beneficially owns 0 shares of Common Stock, representing 0%. The filing provides the filers Malaysia citizenship and a signature dated 03/13/2026.
Bio Green Med Solution, Inc. amendment reports that Kua Khai Loon beneficially owns 0 shares of Common Stock (par value $0.001) representing 0% of the class as of 12/31/2025. The filing lists the reporter's Malaysia residence and provides related warrant exhibits.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., filed an amended current report to correct a presentation detail only. This Amendment No. 1 to the previously filed report updates the cover page to display the company’s correct new logo that aligns with its updated name and ticker symbol, as previously announced. The company states that no other changes have been made to the original report.
Kua Khai Loon, identified on the form as a Director, reported a sale of 19,054 shares of Cyclacel Pharmaceuticals common stock on 09/05/2025 at a price of $7.01 per share. After the reported transaction the filing shows 385,411 shares beneficially owned, held directly. The Form 4 is signed and dated 09/10/2025. The filing discloses the transaction type as a sale and provides the transaction price and post-transaction holdings; no derivative transactions or additional explanatory details are included.
Cyclacel Pharmaceuticals, Inc. reported that shareholders approved all proposals at a special meeting held on September 4, 2025. Investors backed the issuance of Cyclacel common stock to Fitters Parent under an Exchange Agreement, with 1,095,988 votes in favor and a reported 58.8% support level.
Shareholders also approved the potential issuance of more than 20% of the company’s outstanding common stock in connection with a transaction to comply with Nasdaq Listing Rule 5635(a), with similar voting support. In addition, they approved amending the certificate of incorporation to change the company’s name to Bio Green Med Solution, Inc., permit stockholder actions by written consent, ratify prior written-consent actions, and opt out of the business combination provisions of Section 203 of the Delaware General Corporation Law.
Cyclacel Pharmaceuticals, Inc. entered into a Warrant Exchange Agreement with certain accredited investors on September 4, 2025. The company agreed to exchange existing Series C common stock purchase warrants, which were exercisable for an aggregate of 559,395 shares of common stock, for an equal aggregate of 559,395 new shares of common stock issued directly to the holders.
The exchanged warrants were originally issued under a securities purchase agreement dated June 20, 2025. The new shares will be issued without registration under the Securities Act of 1933 in reliance on the Section 3(a)(9) exemption, meaning they are part of a private, unregistered exchange with existing security holders.
Yap Kim Choy, a director of Cyclacel Pharmaceuticals, Inc. (CYCC), exchanged Series C Common Stock Purchase Warrants for common shares on September 4, 2025. The reporting person exchanged 186,465 Series C warrants under a warrant exchange agreement dated September 4, 2025 and received 186,465 shares of Common Stock in return. After the transaction, the reporting person beneficially owned 404,465 shares of Common Stock and held 31,535 Series C warrants remaining. The filing is a Section 16 Form 4 reporting this non-derivative acquisition and related derivative changes.